Iacuzzo Cristiana, Germani Paola, Troian Marina, Cipolat Mis Tommaso, Giudici Fabiola, Osenda Edoardo, Bortul Marina, de Manzini Nicolò
Department of General Surgery, Azienda Sanitaria Universitaria Giuliano-Isontina, Trieste University Hospital, Trieste, Italy.
Department of Medicine, Surgery and Health Sciences, Biostatistics Unit, University of Trieste, Trieste, Italy.
ANZ J Surg. 2021 Jun;91(6):E367-E374. doi: 10.1111/ans.16861. Epub 2021 Apr 18.
Biomarkers may play a role as predictive and prognostic factors in colorectal cancer patients. The aims of the study were to verify the prognostic role of pre-operative serum carcinoembryonic antigen (CEA) level in predicting overall survival and risk of recurrence in a cohort of colorectal cancer patients and to evaluate optimal cut-off values.
A retrospective cohort analysis was performed on colorectal cancer patients undergoing elective curative surgery between 2004 and 2019 at an Italian Academic Hospital. Main outcomes were overall survival, disease-free survival at 3-years and risk of local, loco-regional and distant recurrence during follow-up. A receiver operating characteristic (ROC) curve analysis was plotted using CEA pre-operative values and follow-up data in order to estimate the optimal cut-off values.
A total of 559 patients were considered. The mean CEA value was 12.1 ± 54.1 ng/mL, and the median 29.3 (0-4995) ng/mL. The ROC curve analysis identified 12.5 ng/mL as the best CEA cut-off value to predict the risk of metastatic development after surgery in stage I-III colorectal cancer patients, and 10 ng/mL as the best CEA cut-off value to predict overall survival and disease-free survival in stage III-IV patients. These data suggest a stratification of colorectal cancer patients in three classes of risk: a low risk class (CEA <10 ng/mL), a moderate risk class (CEA 10-12.5 ng/mL) and a high risk class (CEA >12.5 ng/mL).
In conclusion, pre-operative serum CEA measurements could integrate information to enhance patient risk stratification and tailored therapy.
生物标志物可能在结直肠癌患者中作为预测和预后因素发挥作用。本研究的目的是验证术前血清癌胚抗原(CEA)水平在预测一组结直肠癌患者的总生存期和复发风险中的预后作用,并评估最佳临界值。
对2004年至2019年期间在一家意大利学术医院接受择期根治性手术的结直肠癌患者进行回顾性队列分析。主要结局为总生存期、3年无病生存期以及随访期间局部、区域和远处复发风险。使用术前CEA值和随访数据绘制受试者工作特征(ROC)曲线分析,以估计最佳临界值。
共纳入559例患者。CEA平均值为12.1±54.1 ng/mL,中位数为29.3(0 - 4995)ng/mL。ROC曲线分析确定,12.5 ng/mL是预测I - III期结直肠癌患者术后转移发生风险的最佳CEA临界值,10 ng/mL是预测III - IV期患者总生存期和无病生存期的最佳CEA临界值。这些数据表明可将结直肠癌患者分为三类风险:低风险组(CEA <10 ng/mL)、中度风险组(CEA 10 - 12.5 ng/mL)和高风险组(CEA >12.5 ng/mL)。
总之,术前血清CEA检测可整合信息以加强患者风险分层和个体化治疗。